Download PDF
Dialyse aktuell 2016; 20(S 01): s32-s37
DOI: 10.1055/s-0042-122133
Kardiologie/Nephrologie
© Georg Thieme Verlag Stuttgart · New York

Intravenöse Eisengabe bei CKD-Patienten - Kann sie neben der Anämie auch kardiovaskuläre Endpunkte beeinflussen?

Administration of intravenous iron in CKD patients – Does it influence cardiovascular endpoints besides anemia?
Jan-Christoph Galle
1   Klinik für Nephrologie und Dialyseverfahren, Märkische Kliniken GmbH, Klinikum Lüdenscheid
,
Vincent Brandenburg
2   Klinik für Kardiologie, Pneumologie, Angiologie und Internistische Intensivmedizin (Med Klinik I), Uniklinik RWTH Aachen
,
Danilo Fliser
3   Klinik für Innere Medizin IV – Nieren- und Hochdruckkrankheiten, Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
,
Christian Hugo
4   Medizinische Klinik III, Uniklinikum C. G. Carus, TU Dresden
,
Gerhard Lonnemann
5   Nephrologische Gemeinschaftspraxis/Dialyse Langenhagen
,
Hans-Hellmut Neumayer
6   Medizinische Klinik mit Schwerpunkt Nephrologie; Charité Universitätsmedizin Berlin, Campus Charité Mitte
,
Roland Schaefer
7   MVZ Immunologie Frankfurt am Main
› Author Affiliations
Further Information

Publication History

Publication Date:
20 December 2016 (online)

Also available at
    Permissions and Reprints

Herzinsuffizienz (HI) ist die häufigste kardiovaskuläre Diagnose bei Patienten mit chronischer Niereninsuffizienz (CNI) im Endstadium. Ein gemeinsames Begleitsymptom dieser doppelt belasteten und äußerst vulnerablen Patientengruppe ist die Anämie. Aufgrund neuerer Studiendaten mit Eisencarboxymaltose wird intravenöses (i. v.) Eisen auch als Therapieoption bei HI intensiv diskutiert. Damit stellt sich die Frage, ob eine Gabe von i. v. Eisen bei CNI-Patienten mit HI zu erwägen wäre, auch wenn diese unter dem Blickwinkel der reinen Anämiekontrolle eigentlich nicht behandlungsbedürftig sind. Im Hinblick auf die aktuelle Studienevidenz ist es vorerst zu früh, i. v. Eisen bei CNI-Patienten auch zur Therapie einer HI einzusetzen. Aktuell sollte i. v. Eisen auch bei CNI-Patienten mit HI zur Anämietherapie appliziert und die Empfehlungen hinsichtlich der maximalen Serum-Ferritin-Spiegel beachtet werden. Aufgrund der heterogenen Empfehlungen zur Obergrenze ist jedoch eine individuelle Nutzen-Risiko-Analyse für jeden Patienten notwendig.

Intravenous iron is a common treatment option for chronic kidney disease (CKD) patients with anemia. Among end-stage CKD patients, the most common cardiovascular comorbidity is chronic heart failure (CHF). Recent studies suggest a possible benefit of intravenous iron (ferric carboxymaltose) also for patients with CHF irrespective of anemia. Thus, this article discusses the question, whether intravenous iron might also be an option for treatment of CKD/HI patients beyond the scope of anemia treatment. Although it is currently not possible to recommend intravenous iron for HI treatment, it is a valid option for treatment of anemia in CKD/HI patients. Most importantly, maximum serum ferritin levels should be taken into account for therapy according to the latest international guidelines. But due to the very heterogeneous recommendations about this maximum, an individual risk-benefit-evaluation for every patient is mandatory.

Key words

chronic kidney disease - chronic heart failure - anemia - intravenous iron - ferric carboxymaltose
 

  • Literatur

  • 1 U.S. Renal Data System. USRDS 2013 Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States. National Institute of Health, National Institute of Diabetes and Kidney Diseases. Bethesda, MD: 2013
    Google Scholar
  • 2 Mishra RK et al Kansas City Cardiomyopathy Questionnaire Score Is Associated With Incident Heart Failure Hospitalization in Patients With Chronic Kidney Disease Without Previously Diagnosed Heart Failure: Chronic Renal Insufficiency Cohort Study. Circ Heart Fail 2015; 8: 702-708
    CrossrefGoogle Scholar
  • 3 Locatelli F et al Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transpant 2013; 28: 1346-1359
    CrossrefGoogle Scholar
  • 4 National Clinical Guideline Centre. Anaemia Management in Chronic Kidney Disease: Partial update 2015: National Institute for Health and Care Excellence 2015. Stand: 12/2015
    Google Scholar
  • 5 Felker GM et al Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol 2004; 44: 959-966
    CrossrefGoogle Scholar
  • 6 Okonko DO et al Erythropoietin resistance contributes to anaemia in chronic heart failure and relates to aberrant JAK-STAT signal transduction. Int J Cardiol 2013; 164: 359-364
    CrossrefGoogle Scholar
  • 7 Levin A et al Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 2005; 46: 799-811
    CrossrefGoogle Scholar
  • 8 O'Meara E et al Heart failure with anemia: novel findings on the roles of renal disease, interleukins, and specific left ventricular remodeling processes. Circ Heart Fail 2014; 7: 773-781
    CrossrefGoogle Scholar
  • 9 Androne A et al Hemodilution is common in patients with advanced heart failure. Circulation 2003; 107: 226-229
    CrossrefGoogle Scholar
  • 10 Fitzsimons S et al Iron deficiency in patients with heart failure. Eur Heart J Cardiovasc Pharmacother 2015; 1: 58-64
    CrossrefGoogle Scholar
  • 11 Sandek A et al The emerging role of the gut in chronic heart failure. Curr Opin Clin Nutr Metab Care 2008; 11: 632-639
    CrossrefGoogle Scholar
  • 12 Jankowska EA et al Iron status in patients with chronic heart failure. Eur Heart J 2013; 34: 827-834
    CrossrefGoogle Scholar
  • 13 McMahon LP et al Development, prevention, and potential reversal of left ventricularhypertrophy in chronic kidney disease. J Am Soc Nephrol 2004; 15: 1640-1647
    CrossrefPubMedGoogle Scholar
  • 14 Rigatto C et al Electrocardiographic left ventricular hypertrophy in renal transplant recipients: prognostic value and impact of blood pressure and anemia. J Am Soc Nephrol 2003; 14: 462-468
    CrossrefGoogle Scholar
  • 15 Herzog CA et al Impact of congestive heart failure, chronic kidney disease, and anemia on survival in the Medicare population. J Card Fail 2004; 10: 467-472
    CrossrefGoogle Scholar
  • 16 Toblli JE et al Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 2007; 50: 1657-1665
    CrossrefGoogle Scholar
  • 17 Macdougall IC et al FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 2014; 29: 1-10
    CrossrefGoogle Scholar
  • 18 Ponikowski P et al Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2014; 36: 657-668
    Google Scholar
  • 19 Beatty AL et al Six-Minute Walk Test as a Prognostic Tool in Stable Coronary Heart Disease: Data From the Heart and Soul Study. Arch Intern Med 2012; 172: 1096-1102
    Google Scholar
  • 20 Ponikowski P et al The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study. Eur J Heart Fail 2015; 17: 329-339
    CrossrefGoogle Scholar
  • 21 Litton E et al Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. BMJ 2013; 347: f4822
    CrossrefGoogle Scholar
  • 22 Agarwal R et al A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int 2015; 88: 905-914
    CrossrefGoogle Scholar
  • 23 Bailie GR et al Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int 2015; 87: 162-168
    CrossrefGoogle Scholar
  • 24 Minutolo R et al Anaemia management in non-dialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics. Nephrol Dial Transplant 2013; 28: 3035-3045
    CrossrefGoogle Scholar
  • 25 Koperdanova M, Cullis JO. Interpreting raised serum ferritin levels. BMJ 2015; 351: h3692
    Google Scholar